Literature DB >> 495513

Influence of short-term oral hydralazine therapy on exercise hemodynamics in patients with severe chronic heart failure.

S A Rubin, K Chatterjee, T A Ports, H J Gelberg, B H Brundage, W W Parmley.   

Abstract

Changes in left ventricular performance were evaluated in 14 patients with functional New York Heart Association class III or IV chronic heart failure before and after the addition of oral hydralazine to conventional therapy. With conventional therapy, cardiac output increased from 3.4 +/- 0.8 (mean +/- 1 standard deviation) at rest to 4.7 +/- 1.4 liters/min during exercise. This increase in cardiac output on exercise during conventional therapy was mainly due to an increase in heart rate. After the addition of hydralazine, cardiac output at rest increased to 5.0 +/- 1.4 liters/min. The increase in cardiac output was essentially due to an increase in stroke volume. This enhanced stroke volume after hydralazine therapy was maintained during exercise. Hydralazine therapy did not change either the left ventricular filling pressure at rest or the magnitude of increase in left ventricular filling pressure during exercise. Nevertheless, increased cardiac output and stroke volume with similar changes in left ventricular filling pressure during exercise indicated improved left ventricular performance after hydralazine therapy. After short-term hydralazine therapy, symptom-limited peak exercise work load, duration of exercise and maximal oxygen consumption during exercise did not increase. Clinical follow-up at 2 months after long-term therapy revealed subjective improvement in exercise tolerance in 13 of the 14 patients.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 495513     DOI: 10.1016/0002-9149(79)90186-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

Review 1.  Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III.

Authors:  J N Cohn
Journal:  Drugs       Date:  1994       Impact factor: 9.546

2.  Vasodilator treatment with isosorbide dinitrate and hydralazine in chronic heart failure.

Authors:  B M Massie; B Kramer; E Shen; F Haughom
Journal:  Br Heart J       Date:  1981-04

Review 3.  The treatment of heart failure. A methodological review of the literature.

Authors:  G H Guyatt
Journal:  Drugs       Date:  1986-12       Impact factor: 9.546

4.  Short- and long-term effects of hydralazine and combined hydralazine-prenalterol therapy in severe chronic congestive heart failure.

Authors:  H Drexler; H Löllgen; H Just
Journal:  Klin Wochenschr       Date:  1981-06-15

5.  The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure.

Authors:  G H Guyatt; M J Sullivan; P J Thompson; E L Fallen; S O Pugsley; D W Taylor; L B Berman
Journal:  Can Med Assoc J       Date:  1985-04-15       Impact factor: 8.262

Review 6.  Vasodilator therapy in chronic congestive heart failure.

Authors:  A B Schwartz; K Chatterjee
Journal:  Drugs       Date:  1983-08       Impact factor: 9.546

Review 7.  Vasodilator therapy without converting-enzyme inhibition in congestive heart failure--usefulness and limitations.

Authors:  W J Remme
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 8.  Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure.

Authors:  J P Mulrow; M H Crawford
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.